文献速递产科母胎医学

硝苯地平维持性宫缩抑制治疗先兆早产后儿童学业表现:APOSTEL 2 试验 12 年随访

School Performance After Maintenance Tocolysis With Nifedipine for Threatened Preterm Birth: 12-Year Follow-Up of the APOSTEL 2 Trial.
PubMed 文献 · BJOG · 2025-09-29

该研究为 APOSTEL 2 试验的 12 年随访,评估产前暴露于硝苯地平维持性宫缩抑制治疗与安慰剂对儿童 12 岁时学业表现的影响。共纳入 357 名儿童,硝苯地平组获得高等级中学轨道推荐的比例显著低于安慰剂组(35.4% vs 44.0%,aRR 0.76)。结论认为产前硝苯地平维持性宫缩抑制治疗与 12 岁时学业表现较差相关。

要点

  • 硝苯地平组高等级中学轨道推荐比例 35.4%(67/189),安慰剂组 44.0%(74/168),aRR 0.76。
  • 暴露时间最长(9-14 天)的儿童结局显著更差,与未暴露者相比 aRR 0.58。
  • 研究结果进一步不支持使用硝苯地平进行维持性宫缩抑制治疗。

核心结论

  • 产前暴露于硝苯地平维持性宫缩抑制治疗的儿童 12 岁时学业表现显著差于安慰剂暴露儿童。
  • 这些发现进一步不支持硝苯地平用于维持性宫缩抑制治疗,其对孩子发育的长期影响需要更多研究。

研究设计与样本

  • 研究为多中心 APOSTEL 2 试验的 12 年随访,该试验在 2008 至 2010 年于 11 家荷兰医院开展。
  • 纳入孕 26+0 至 32+2 周先兆早产、初始 48 小时宫缩抑制治疗后仍妊娠的孕妇,随机接受硝苯地平维持性宫缩抑制治疗或安慰剂,最长 12 天。
  • 纳入单胎和多胎妊娠分娩的儿童,通过与国家登记处(Statistics Netherlands)链接获取学业表现数据。

主要发现

  • 492 名合格儿童中纳入 357 名,随访率 73%。
  • 硝苯地平组获得高等级中学轨道推荐的儿童为 67/189(35.4%),安慰剂组为 74/168(44.0%),校正后风险比(aRR)0.76,95% 置信区间(CI)0.61-0.95。
  • 硝苯地平暴露时间最长(9-14 天)的儿童与未暴露儿童相比,结局显著更差(aRR 0.58;95% CI 0.41-0.83)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate school performance at 12 years of age in children prenatally exposed to maintenance tocolysis with nifedipine versus placebo. DESIGN: 12-year follow-up of the multicentre APOSTEL 2 trial, in which participants with threatened preterm birth between 26+0 and 32+2 weeks of gestation, who remained pregnant after initial 48-h tocolysis, were randomised to nifedipine maintenance tocolysis or placebo for up to 12 days. SETTING: The APOSTEL 2 trial was conducted in 11 Dutch hospitals from 2008 to 2010. School outcomes were assessed at age 12. PARTICIPANTS: Children from singleton and multiple pregnancies born to APOSTEL 2 participants. METHODS: School performance data were received through linkage with a national registry (Statistics Netherlands). MAIN OUTCOME MEASURES: A high track recommendation for secondary school, adjusted for maternal education level, socioeconomic status, and child's biological sex. RESULTS: Of 492 eligible children, 357 were included (follow-up rate 73%). In the nifedipine group, significantly fewer children received a high track recommendation for secondary school, 67/189 (35.4%), compared to 74/168 (44.0%) in the placebo group (adjusted risk ratio (aRR) 0.76; 95% confidence interval (CI) 0.61-0.95). Outcomes were significantly poorer in children with the longest nifedipine exposure (9-14 days) compared to those not exposed (aRR 0.58; 95% CI 0.41-0.83). CONCLUSIONS: Children prenatally exposed to maintenance tocolysis with nifedipine had significantly poorer school performance at 12 years of age compared to those exposed to placebo. These findings further discourage nifedipine's use for maintenance tocolysis, and more research is warranted regarding its long-term effects on child development.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. van der Windt LI, Meliezer JAL, Pajkrt E, et al. School Performance After Maintenance Tocolysis With Nifedipine for Threatened Preterm Birth: 12-Year Follow-Up of the APOSTEL 2 Trial. BJOG. 2025. PMID: 41017487. doi:10.1111/1471-0528.70030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。